Novel Therapeutic Approaches to Improve Outcomes for Patients with PAH

AMA/ANCC/ACPE Activity

Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Currently, therapies for treating pulmonary hypertension have been used alone and in combination to demonstrate improvements in quality of life and hemodynamic parameters as well as in slowing disease progression; however, beneficial effects on survival are limited. None offer a cure against PAH nor directly address the underlying cellular proliferation that leads to increased pulmonary arterial pressure, and the median survival rate remains at 61% at five years after diagnosis. Extensive research efforts have led to the emergence of innovative therapeutic approaches in PAH. This on-demand webcast focuses on several important aspects of PAH management, including a discussion of the challenges diagnosing and treating patients, clinical trial data on emerging therapeutics for the management of PAH, and a review of strategies to optimize outcomes for patients with PAH.

Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Activity Faculty

	Aaron Waxman, MD, PhD, FACP, FCCP Director, Pulmonary Vascular Disease Program Executive Director, Center for Pulmonary Heart Diseases Brigham and Women's Hospital, Heart and Vascular Center
	Mardi Gomberg-Maitland, MD, MSc Chief Research Officer George Washington Office of Clinical Research Director, Pulmonary Hypertension George Washington University School of Medicine and Health Sciences